1,4-Butanediamine, N-[2-(aminooxy)ethyl]- | 131602-71-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,4-Butanediamine, N-[2-(aminooxy)ethyl]-
• 英文别名: O-[2-(4-aminobutylamino)ethyl]hydroxylamine
• CAS: 131602-71-6
• 化学式: C₆H₁₇N₃O
• mdl: MFCD19212527
• 分子量: 147.22
• InChiKey: ARIJWDLLMYRQKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  10
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  73.3
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  丙酮基-辅酶 A 、 1,4-Butanediamine, N-[2-(aminooxy)ethyl]- 生成
  参考文献：
  名称：

  Novel CoA-Polyamine Conjugates for Effective Inhibition of Spermine/Spermidine-N¹-Acetyltransferase

  摘要：

  New mimics of the transition state of spermine/spermidine-N(1)-acetyltransferase reaction were prepared starting from aminooxy analogues of spermidine or spermine and SH-CoA. The activity depended on the structure of polyamine fragment of the conjugate and best of the synthesized compounds were active at micromolar concentrations.

  DOI：

  10.1080/15257770701528214

文献信息

• [EN] POLYAMINE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE<br/>[FR] INHIBITEUR DE POLYAMINE POUR LE TRAITEMENT ET LA PRÉVENTION DE LA MALADIE DE PARKINSON
  申请人：UNIV COLUMBIA

  公开号：WO2010098886A1

  公开（公告）日：2010-09-02

  Disclosed herein are methods for treating a disease involving α-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α- synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Also disclosed are methods for reducing the amount of α-synucleic aggregation in a brain cell using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α-synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Disclosed herein are also compounds which can be used in the above described methods.

  本文揭示了治疗涉及α-突触核聚集的疾病的方法，使用以下物质之一：（1）减少多胺量的化合物，以有效减少α-突触核聚集；（2）抑制多胺合成的化合物，以有效减少α-突触核聚集；或（3）抑制α-突触核聚集的化合物，以有效减少α-突触核聚集。还揭示了一种在脑细胞中减少α-突触核聚集量的方法，使用以下物质之一：（1）减少多胺量的化合物，以有效减少α-突触核聚集；（2）抑制多胺合成的化合物，以有效减少α-突触核聚集；或（3）抑制α-突触核聚集的化合物，以有效减少α-突触核聚集。本文还揭示了可用于上述方法的化合物。
• [EN] POLYAMINE PRODRUGS AND POLYAMINE PRODRUG FORMULATIONS<br/>[FR] PROMÉDICAMENTS DE POLYAMINE ET FORMULATIONS DE PROMÉDICAMENT DE POLYAMINE
  申请人：UNIV NEBRASKA

  公开号：WO2019173446A1

  公开（公告）日：2019-09-12

  Provided herein are copolymers comprising monomers of a polyamine and a degradable linker, and further comprising a stabilizing moiety, a fluorinated moiety, a poly(ethylene glycol) (PEG) which is optionally substituted with a targeting moiety, or a combination thereof. Also provided are nanoparticles comprising copolymers as described herein, and methods of using the copolymers and nanoparticles for treating diseases or disorders, e.g., Snyder Robinson Disease or cancer.

  本文提供了由聚胺和可降解连接剂单体组成的共聚物，进一步包括稳定基团、氟化基团、聚乙二醇（PEG），可选择用靶向基团替代，或其组合。本文还提供了包括上述共聚物的纳米粒子，并提供了使用这些共聚物和纳米粒子治疗疾病或疾病的方法，例如Snyder Robinson病或癌症。
• METHYLGLYOXAL BIS(GUANYL-HYDRAZONE) FOR REGULATING OSTEOPONTIN IN A SUBJECT
  申请人：Pathologica LLC

  公开号：EP3228310A1

  公开（公告）日：2017-10-11

  The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.

  本发明提供了调节受试者体内骨化素活性以及治疗或预防与受试者体内骨化素活性增加有关的疾病的方法。
• COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS
  申请人：Pathologica LLC

  公开号：EP3473247A1

  公开（公告）日：2019-04-24

  The present invention relates to an oral pharmaceutical composition, comprising methylglyoxal bis(guanylhydrazone) (MGBG) together with at least one oral pharmaceutically acceptable excipient, for use in the treatment or delaying the onset or development of multiple sclerosis when orally administered to a subject.

  本发明涉及一种口服药物组合物，包括甲基乙二醛双（鸟苷腙）（MGBG）和至少一种口服药物可接受赋形剂，用于口服给受试者治疗或延缓多发性硬化症的发作或发展。
• MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS
  申请人：Pathologica LLC

  公开号：EP3831372A1

  公开（公告）日：2021-06-09

  Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.

  本文公开了SAMDC抑制剂、多胺类似物和多胺生物合成抑制剂的新型口服药物组合物，以及它们在治疗脱髓鞘疾病、影响神经系统的自身免疫性疾病和其他神经退行性疾病等疾病中的应用。